Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Key Inclusion Criteria: * Be able to understand and voluntarily sign informed consent * A diagnosis GD, either Type 1 or Type 3 * For GD3 at least 1 neurological symptom * Age ≥ 4 years and ≤ 60 years at the time of enrolment * Plasma or serum chitotriosidase activity greater than 3 times the upper limit of normal. Key Exclusion Criteria: * Recipient of a liver transplant or planned liver transplantation during the course of the study. * Splenectomy within 4 months of study entry or planned splenectomy during the course of the study. * Severe liver damage. * Severe renal insufficiency. * Body weight \< 10 kg. Other inclusion and exclusion criteria may apply